 - Patient who has had chemotherapy, radiotherapy or hormonal therapy within 3 weeks 6 weeks for nitrosoureas, mitomycin C or bevacizumab, or who has not recovered from the adverse events due to previous agents administered more than 4 weeks prior to Study Day 1. If the patient has residual toxicity from prior treatment, toxicity must be Grade 1. 